KRAS and cancer: HA-TPP, a self-assembled nanocarrier composed of hyaluronic acid (HA) and lipophilic alkyltriphenylphosphonium (TPP), targets mitochondria and promotes mutp53 degradation, showing synergistic effects when combined with KRAS inhibitors like AMG510 in KRAS/TP53-mutated cancers [132].